Adding bempedoic acid to rosuvastatin and ezetimibe before planned artery procedures
Adds bempedoic acid to cholesterol treatment in people with artery disease.
Plain-language title generated from the registry record
Registry title: Early TRIPLE versus dual LIPID lowering treatment in peOple with atherosclerotic cardiovascular disease and hypercholesterolemia Undergoing elecTive revascularisation
Key facts
- Where
- Feldkirch, Graz, and Klagenfurt Am Woerthersee, AustriaSee the 4 sites
- Phase
- Phase 4
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults aged 18 to 80 with heart or leg artery disease and high cholesterol who are planning a scheduled procedure to reopen blocked arteries.
- Age
- 18 to 80 years, both included
- Sex
- All sexes can join.
- Disease stage
- Atherosclerotic cardiovascular disease with an indication for coronary or peripheral artery revascularisation.
- Earlier treatment
- Must tolerate statin treatment; on rosuvastatin 20 mg OD, a stable dose for 6 weeks before Visit 1 if entering directly. No ezetimibe, bempedoic acid or PCSK9 inhibitor in the last 8 weeks, and no inclisiran in the last 12 months.
- Biomarker or test result
- LDL-C at Visit 1 above 55 mg/dl and below 100 mg/dl while on rosuvastatin 20 mg OD.
Main reasons for not taking part
- Known intolerance to statins, ezetimibe or bempedoic acid
- eGFR below 30 ml/min/1,73m2
- History or presence of acute coronary syndrome, acute limb ischaemia or acute stroke
- Known active cancer (basalioma and intraepithelial neoplasia are excluded)
- Pregnancy, breastfeeding, or women of childbearing potential without adequate contraception
Read by machine on 9 November 2026.
Where in Austria
- VIVITFeldkirch, AustriaTaking people
- Medical University of GrazGraz, AustriaTaking people
- Steiermaerkische Krankenanstalten Ges.m.b.H.Graz, AustriaTaking people
- Landeskrankenanstalten-Betriebsgesellschaft KabegKlagenfurt Am Woerthersee, AustriaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record
Print a page for my doctorTrial details
- Who runs it
- Medical University Of Graz
- Trial code
- EU 2026-525917-29-00
- Record updated
- 17 July 2026
- Original description
The primary objective is to investigate the percentage of trial participants achieving an LDL-C <55 mg/dl on either a triple lipid lowering treatment including rosuvastatin 20 mg OD, ezetimibe 10 mg OD and bempedoic acid 180 mg OD compared to a dual therapy of rosuvastatin 20 mg OD and ezetimibe 10 mg ODRead full original descriptionShow less
Early TRIPLE versus dual LIPID lowering treatment in peOple with atherosclerotic cardiovascular disease and hypercholesterolemia Undergoing elecTive revascularisation - The randomized, controlled, open-label, parallel group TRIPLE-LIPID-OUT trial
The primary objective is to investigate the percentage of trial participants achieving an LDL-C <55 mg/dl on either a triple lipid lowering treatment including rosuvastatin 20 mg OD, ezetimibe 10 mg OD and bempedoic acid 180 mg OD compared to a dual therapy of rosuvastatin 20 mg OD and ezetimibe 10 mg OD
Inclusion: Age between 18 and 80 years, both inclusive; Informed consent has to be given in written form; Atherosclerotic cardiovascular disease with an indication for coronary or peripheral artery revascularisation; LDL-C at Screening (Visit S – only required, if trial participant is on no or other statin treatment than rosuvastatin 20 mg OD) in the following range depending on lipid lowering treatment: - LDL-C >130 mg/dl and <170 mg/dl when on no lipid lowering treatment - LDL-C >70 mg/dl and <110 mg/dl when pretreated with either simvastatin 40 mg, atorvastatin 10-20 mg or rosuvastatin 10 mg monotherapy - LDL-C >55 mg/dl and <100 mg/dl when pretreated with either atorvastatin 40 mg or rosuvastatin 20 mg - LDL-C >55 mg/dl and <85 mg/dl when pretreated with either atorvastatin 80 mg OD or rosuvastatin 40 mg; LDL-C at V1 >55 mg/dl and <100 mg/dl while on rosuvastatin 20 mg OD; Tolerability of statin treatment during the run-in phase or if participants enter the study directly at Visit 1, tolerability of a stable rosuvastatin 20 mg OD treatment over 6 weeks prior to Visit 1.
Exclusion: Treatment with ezetimibe, bempedoic acid or an PCSK9 inhibitor within the last 8 weeks or inclisiran within the last 12 months; Females of childbearing potential without adequate contraceptive methods (i.e. sterilisation, intrauterine device, vasectomised partner; or medical history of hysterectomy); Conditions that prevent people from following the study procedures; History or presence of acute coronary syndrome; History or presence of acute stroke; eGFR <30 ml/min/1,73m2; AST or ALT > 3 times upper limit or normal; Fasting triglycerides >400 mg/dl; Trial participant has participated in another study of an investigational medication or an investigational medical device (except for observational studies using continuous glucose monitoring devices) within the last 30 days or is currently participating in these studies; History or acute episode of gout; Known intolerance for statins, ezetimibe or bempedoic acid; Known homozygous familial hypercholesterolaemia; Known alcohol abuse (more than 15 drinks / week); Known active carcinoma (basalioma and intraepithelial neoplasia are excluded); History or presence of acute limb ischaemia; Pregnancy or intention of becoming pregnant or breastfeeding women.